Merck Not Feeling Mega-Merger Mania Even As Pharma Sales Decline
This article was originally published in The Pink Sheet Daily
Executive Summary
Patent expiries for five products drag down revenue, but biotech deals and pipeline building remain Merck’s strategy, CEO Frazier says.
You may also be interested in...
PCSK9s Get Boost From IMPROVE-IT; Outcomes Data Restores Faith In LDL Surrogate
Reduction in events with Merck’s Zetia as add-on therapy despite a modest LDL-lowering effect bodes well for Sanofi/Regeneron and Amgen’s PCSK9 inhibitors, which have large effects on LDL.
Emerging Markets Earnings Roundup: Merck, Bristol Myers Squibb, Novo Nordisk (Part 12)
Merck played cat and mouse on the first quarter earnings call, but its subsequent deal with Bayer put the remarks in context. Bristol Myers Squibb has to wait on China for approval there of its diabetes deal with AstraZeneca and Novo Nordisk gets hit by emerging market currencies.
Emerging Markets Earnings Roundup: Merck, Bristol Myers Squibb, Novo Nordisk (Part 12)
Merck played cat and mouse on the first quarter earnings call, but its subsequent deal with Bayer put the remarks in context. Bristol Myers Squibb has to wait on China for approval there of its diabetes deal with AstraZeneca and Novo Nordisk gets hit by emerging market currencies.